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To evaluate functional recovery in 20 consecutive pa-
tients with acute myocardial infarction who received re-
combinant tissue-type plasminogen activator, serial two-
dimensional echocardiograms were performed before and 
immediately after tissue plasminogen activator admin-
istration and at 1 and 10 days postinfarction. Tissue 
plasminogen activator was administered intravenously 
(17 patients) or by intracoronary infusion (3 patients) 
after angiographic confirmation of total occlusion. Re-
perfusion, documented by angiography, occurred in 13 
of the 20 patients. The mean time from onset of chest 
pain to thrombolysis was 5.1 ± 1.1 hours. Echocardio-
grams were evaluated for regional function with a visual 
semiquantitative scoring system by two independent ob-
servers who had no knowledge of patient identity, tem-
poral sequence, therapy or effect of therapy. 
There was no immediate or 24 hour improvement in 
wall motion. At day 10 compared with pretreatment, 28 
of 33 reperfused infarct zone segments versus 6 of 20 
nonreperfused infarct segments demonstrated improved 
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wall motion (p = 0.01). This improvement did not relate 
to time from onset of chest pain to successful throm-
bolysis. Of reperfused infarct zone segments in the dis-
tribution of coronary artery balloon dilation, 19 of 23 
segments exhibited improvement versus 7 of 17 (reper-
fused, no angioplasty) and 6 of 20 (nonreperfused, no 
angioplasty) segments (p = 0.001). Infarct zone seg-
ments reperfused at the time of ongoing chest pain dem-
onstrated functional recovery compared with segments 
reperfused in the absence of chest pain (18 of 23 versus 
10 of 20, respectively; p = 0.05). 
Thus, in this uncontrolled series, there was echocar-
diographically detectable improvement in function of re-
perfused infarct segments 10 days after coronary throm-
bolysis with recombinant tissue plasminogen activator. 
The functional recovery occurred predominantly in pa-
tients who also had coronary artery balloon dilation or 
ongoing chest pain, or both, at the time of coronary 
thrombolysis. 
(J Am Coli CardioI1985;6:426-33) 
During the past 5 years, there has been scientific interest in 
applying thrombolytic therapy to patients with acute myo-
cardial infarction (1-3). With intracoronary streptokinase, 
recanalization of the acutely occluded coronary artery has 
been demonstrated to be successful in up to 80% of patients 
(4-8). Despite reperfusion, however, only a few controlled 
studies have shown beneficial effects on left ventricular 
function and many have shown no measurable benefit 
(5.9-14). Recombinant tissue-type plasminogen activator is 
a human enzyme that holds promise for the treatment of 
acute coronary thrombosis by virtue of its relative clot-
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selectivity, short half-life and little potential for antigenicity 
(15-18). We recently participated in a multicenter pilot 
study of tissue plasminogen activator in acute myocardial 
infarction (19). During this study, in addition to determining 
the coronary thrombolytic efficacy of this agent, we directed 
our attention to whether successful coronary thrombolysis, 
together with methods to maintain arterial patency, could 
affect functional recovery of myocardium. 
Methods 
Selection of patients. Patients who presented to Johns 
Hopkins Hospital and the Francis Scott Key Medical Center 
with chest pain of greater than 20 minutes' but less than 6 
hours' duration, associated with 1 mm or greater electro-
cardiographic ST segment elevation (in one or more leads), 
were considered for entry into the protocol. Exclusion cri-
teria were: cardiogenic shock, prior coronary artery bypass 
surgery, bleeding diathesis, prior transmural myocardial in-
farct, age greater than 70 years, pregnancy or significant 
hepatic, renal or pUlmonary disease. 
Coronary arteriography and thrombolysis. After giv-
ing informed consent, patients underwent selective coronary 
arteriography using the Judkins technique. Once arterial 
access was obtained, heparin (100 U/kg body weight, max-
imum 10,000 U) was infused intravenously. Coronary an-
giograrns were obtained in the oblique and several hemiaxial 
projections for both the infarct vessel and the contralateral 
coronary artery. Total occlusion was confirmed angiograph-
ically in 21 of 34 patients so studied. The study drug (tissue 
plasminogen activator [0.25 to 0.75 mg/kg over 30 to 120 
minutes] or saline solution placebo) was administered in-
travenously to these 21 patients. Thirty minutes after the 
start of the infusion, the study was unblinded. If placebo 
had been infused and there was no evidence of recanalization 
during the placebo infusion (this occurred in three patients), 
the patient was crossed over to treatment with intracoronary 
tissue plasminogen activator infusion (0.375 mg/kg over 15 
to 30 minutes). In one patient, reperfusion was observed 
during the placebo infusion. Because this patient never re-
ceived tissue plasminogen activator, the data are not in-
cluded in this series (19). The remaining 20 consecutive 
patients were entered into the protocol. Relevant charac-
teristics are summarized in Table 1. 
Coronary angioplasty. All patients who had successful 
recanalization with tissue plasminogen activator were con-
sidered for percutaneous transluminal coronary angioplasty. 
The criteria for selection were 1) a discrete lesion that ap-
peared amenable to dilation in the infarct vessel and 2) lack 
of diffuse or severe atherosclerotic disease of the noninfarct-
related vessels. Coronary angioplasty was performed at a 
mean of 22 (± 21) hours after successful thrombolysis. It 
was not performed immediately after thrombolysis in seven 
of nine patients because of the time required to transfer the 
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Table 1. Patient and Therapy Characteristics 
Patients 
Number 
Age (yr) 
Mean 
Range 
Sex (male/female ratio) 
Site of infarct (no. of patients) 
Anterior 
Inferior 
Drug therapy 
Dose of t-PA (mg) 
Route (no. of patients) 
Intravenous 
Intracoronary 
Hours from chest pain to t-PA 
Hours from chest pain to lysis 
Successful lysis 
All patients 
Patients with inlravenous t-PA 
20 
55 ± 7 
(39 to 69) 
17:3 
9 
II 
43 ± 17 
17 
3 
4.8 ± 1.5 
5.1 ± 1.1 
13 of 20 (65%) 
12 of 17 (71%) 
Lysis '= coronary artery recanalization; t-PA = recombinant tis~e­
type plasminogen activator. 
patient between hospitals or obtain cardiothoracic surgical 
backup. All patients with tissue plasminogen activator-me-
diated thrombolysis were placed on a medical regimen to 
prevent rethrombosis, consisting of intravenous heparin (1,000 
U/h), aspirin (325 mg/day), dipyridamole (75 mg three 
times/day) and nifedipine (10 mg four times/day). Heparin 
was continued for the initial 4 to 5 hospital days; antiplatelet 
and calcium channel antagonist therapy were utilized 
throughout the hospital course. 
Echocardiography. Two-dimensional echocardiogra-
phy was performed before administration of tissue plas-
minogen activator, serially every 15 minutes for 2 hours 
after the infusion was complete and at :24 hours and 8 to 
10 days postinfarction. The Hewlett-Packard ultrasonograph 
(AC-77020) was used for 16 patients and the Diasonics 
3400R for the remaining 4 patients. Each two-dimensional 
study consisted of parasternal long- and short-axis views 
(the latter at two cross-sectional levels) and apical two and 
four chamber views. In patients in whom these views were 
suboptimal, the subxiptlOid window was utilized. Using a 
combination of these views, all studies were technically 
adequate for scoring regional endocardial wall motion. 
For the purpose of analysis, the left ventricle was divided 
into seven segments (Fig. J). Each study was recorded on 
videotape and later scored independently by two observers 
who were unaware of patient identity, temporal se~c 
in which the studies were acquired, therapy and effects of 
therapy (thrombolysis or no thrombolysis, angioplasty or 
no angioplasty). Each myocardial segment was scored for 
wall motion using semiquantitative visual analysis grading 
for dyskinesia, akinesia, hypokinesia and nonnal motion 
(20). Improvement was defined by at least one full increase 
in grade, from akinesia to hypokinesia or hypokinesia to 
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Figure 1. Schematic diagram showing the method used to identify 
seven myocardial segments from the long- and short-axis para-
sternal (above) and apical four and two chamber (below) echo-
cardiographic views. I = basal septal, 2 = mid apical septal, 3 
= apical, 4 = diaphragmatic, 5 = posterobasal, 6 = superolateral 
and 7 = inferolateral. MV = mitral valve level; PAP = papillary 
muscle level. 
normal wall motion. The infarct zone was defined by match-
ing echocardiographic territory to the distribution of the 
occluded coronary artery, as defined by coronary arteriog-
raphy. The regions not supplied by the totally occluded 
coronary artery were considered the noninfarct zone. Non-
infarct zone segments were not scored for hyperkinesia; 
when it was present (in 7 of 77 segments), the segment was 
graded as having normal wall motion. In scoring, there was 
lack of observer agreement on 14% of segments; this was 
resolved by joint review of the study and consensus. 
Statistical analysis. All values reported are mean ± 
standard deviation of the mean. Chi-square analysis, with 
either a 2 x 2 or 2 x 3 contingency table, was utilized to 
determine whether there was a significant difference be-
tween functional wall motion improvement in the reperfused 
and nonreperfused infarct zones and the noninfarct zone. 
Results 
Thrombolysis. Coronary reperfusion with tissue plas-
minogen activator was successful in 13 (65%) of the 20 
patients. The time from onset of chest pain to angiograph-
ically determined lysis was 5.1 ± 1.1 hours. Tissue plas-
minogen activator was administered intravenously in 17 pa-
tients and by the intracorQnary route in 3 patients after no 
lysis was observed during the 30 minute placebo infusion. 
Reperfusion was achieved in 12 of the 17 patients who 
received tissue plasminogen activator intravenously, but in 
only 1 of the 3 who received the enzyme by intracoronary 
infusion. The mean dose of tissue plasminogen activator 
was 43 ± 17 mg (range 0.25 to 0.75 mg/kg over 30 to 120 
minutes). In patients with successful reperfusion, recanal-
ization of the infarct vessel occurred 36 ± 10 minutes after 
the start of tissue plasminogen activator infusion. Six of 13 
patients with reperfusion had ongoing chest pain at the time 
of angiographic recanalization. Visible collateral channels 
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to the distal territory of the infarct vessel were notec! in 4 
of the 13 patients. Of the six patients who c!id not exhibit 
recanalization, three had evidence of collateralization to the 
infarct vessel. At the time of angiographic lysis, electro-
cardiographic Q waves and persistent ST segment elevation 
were present in four and eight patients, respectively. 
Percutaneous transluminal coronary angioplasty (Ta-
ble 2). Nine of the 13 patients in whom reperfusion oc-
curred returned to the catheterization laboratory for coronary 
angioplasty. At that time, two of the nine patients dem-
onstrated reocclusion, without associated symptoms, despite 
an intensive medical antithrombotic regimen. In these two 
patients, dilation of the infarct vessel by angioplasty was 
unsuccessful. Of the seven patients who had successful in-
farct vessel dilation by angioplasty, five had normal findings 
on a predischarge submaximal exercise treadmill test (max-
imal heart rate 120 beats/min). An equivocal test in two 
patients led to repeat coronary angiography, which dem-
onstrated a widely patent vessel in both patients. In follow-
up, one patient died after a massive stroke that occurred 18 
days postinfarction; the other six patients with successful 
coronary artery dilation are asymptomatic and have returned 
to work at 9 ± 2 months postinfarction. 
Four patients in whom thrombolysis was achieved were 
not considered candidates for coronary angioplasty for the 
following reasons: one patient with two vessel disease had 
two clinical reocclusive episodes within 6 hours after tissue 
plasminogen activator infusion, manifested by recurrence 
of chest pain and electrocardiographic ST segment eleva-
tion, and underwent emergent surgical revascularization 
successfully; three patients had severe, diffuse three vessel 
coronary artery disease, one of whom died of cardiogenic 
shock and massive hemorrhagic infarction on the fifth day 
after infarction. 
Reocclusion. In addition to the two patients who exhib-
ited "silent" reocclusion detected at the time of attempted 
coronary angioplasty, the patient who died of cardiogenic 
shock demonstrated a total left anterior descending artery 
Table 2. Results of Coronary Angioplasty After Thrombolysis 
Site of dilation 
(no. of patients) 
Time postinfarct (hours) 
Success of dilation 
Change in percent stenosis 
Predischarge ETT 
(no. of patients) 
Follow-up status 
LAD in 4, RCA in 5 
22 ± 21 
7 of 9 (77%)* 
84±6to29±7 
Negative in 7 of 7 
Asymptomatic in 6 of 7 patientst; 
9 ± 2.1 (mo) 
*Of the two patients in whom coronary angioplasty was not successful, 
both had reocclusion without associated symptoms before the procedure. 
tOne patient sustained a massive stroke 2 weeks after hospital discharge. 
ETT = submaximal treadmill exercise test; LAD = left anterior descend-
ing coronary artery; RCA = right coronary artery. 
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thrombotic occlusion at autopsy. The other patient who de-
veloped recurrent chest pain and ST segment elevation re-
sponsive to intravenous streptokinase was demonstrated to 
have intracoronary thrombus at the time of surgical 
revascularization. 
Regional function: immediate and 24 hours (Fig. 2). 
The changes in regional function from pretreatment to im-
mediately after treatment and to 24 hours later were similar. 
At 1 hour after tissue plasminogen activator infusion, no 
improvement of wall motion was found in 28 of 43 reper-
fused infarct zone segments compared with 15 of 20 non-
reperfused infarct segments and 68 of 77 noninfarct seg-
ments (p = NS). One day after tissue plasminogen activator 
was administered, lack of functional improvement was ev-
ident in 30 of 43 reperfused infarct regions, 16 of 20 non-
recanalized infarct segments and in 69 of 77 segments of 
the noninfarct zone (p = NS). Thus, there was no detectable 
immediate or 24 hour improvement in regional wall motion 
after tissue plasminogen activator infusion. The scoring of 
noninfarct zone segments served as a control and showed 
no significant change throughout the 10 day study period. 
Regional function at 10 days (Fig. 3 to 6). In contrast 
to the immediate and 24 hour results, wall motion at 10 
days was significantly more improved in reperfused infarct 
zone segments than in nonreperfused segments (improve-
ment in 28 of 43 versus 6 of 20, respectively; K = 6.7, 
P = 0.01) (Fig. 3). An example of echocardiographic im-
provement in segmental motion is shown in Figure 4. The 
greatest functional improvement of the reperfused infarct 
segments occurred in the subgroup that underwent both suc-
cessful thrombolysis and coronary angioplasty (Fig. 5). Re-
gional wall motion improvement was evident in 19 of 23 
reperfused infarct segments that were also in the distribution 
of coronary artery balloon dilation, but in only 7 of 17 "lysis 
only" and 6 of 20 nonreperfused infarct zone segments (K 
= 13.3, P = 0.001). There were no intergroup differences 
in functional improvement for reperfused versus nonreper-
Figure 2. Lack of improvement of segmental wall motion at 24 
hours compared with pretreatment. There was no difference be-
tween the number of reperfused or nonreperfused infarct segments 
that exhibited improvement. Minimal change in wall motion (no 
improvement) was apparent in the noninfarct zone. 
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Figure 3. At 10 days, compared with baseline, there is signifi-
cantly greater wall motion improvement in reperfused than in non-
reperfused infarct zone segments. 
fused infarct segments with regard to the presence or absence 
of pretreatment visible collateral vessels, electrocardio-
graphic Q waves or persistent ST segment elevation (con-
current with tissue plasminogen activator therapy). How-
ever, in those patients with ongoing chest pain at the time 
of coronary thrombolysis, there was greater improvement 
in the reperfused infarct zone segments in patients with chest 
pain at 10 days postinfarction (Fig. 6). At 10 days, wail 
motion improvement was detected in 18 of 23 reperfused 
infarct segments in patients with chest pain at the time of 
coronary thrombolysis versus 10 of 20 reperfused infarct 
segments in patients without chest pain (p = 0.05, Fisher's 
exact test). 
Functional recovery: lack of time dependency of re-
perfusion (Fig. 7). There is marked scatter in the change 
of wall motion score (10 days compared with pretreatment) 
for all infarct zone segments reperfused within a range of 
3 to 7 hours from the onset of chest pain. This suggests that 
in this small series of patients, no trend was established that 
correlated early reperfusion with functional recovery of in-
farct segments. 
Discussion 
Using two-dimensional echocardiography, we have dem-
onstrated the absence of detectable regional wall improve-
ment immediately and 24 hours after treatment of acute 
coronary occlusion with recombinant tissue-type plasmin-
ogen activator. However, 10 days after treatment, there was 
an improvement in segmental motion of the reperfused com-
pared with the nonreperfused infarct zones. This occurred 
chiefly in patients who had both successful plasminogen 
activator-mediated coronary thrombolysis and angioplasty. 
In addition, although the time from onset of chest pain to 
thrombolysis did not correlate with functional recovery, in-
farct zone segments that were reperfused while the patient 
had ongoing chest pain exhibited greater improvement in 
regional wall motion than did those of patients without chest 
pain at the time of reperfusion. 
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Figure 4. Two-dimensional echocardiograms of a 
patient who presented with proximal left anterior 
descending artery occlusion and underwent suc-
cessful thrombolysis and coronary angioplasty. A, 
Baseline study, parasternal long-axis view in di-
astole, demonstrates mid- and distal septal deform-
ity (arrow). B, Corresponding systolic frame shows 
lack of inward endocardial movement (arrow) and 
binge point at proximal septum (arrowhead). C, 
Study at 10 days postitifarction, parasternal long-
axis view in diaStole, demonstrates normal cavity 
configuration. D, Corresponding systolic frame 
demonstrates normal endocardial motion of the mid-
and distal septal Segments. 
Comparison with previous studies. The finding that 
regional myocardial ftinction is unchanged immediately and 
1 day after successful coronary thrombolysis is in agreement 
with most experimental animal investigations (21-24) and 
clinical studies (4,12,25) with streptokinase treatment for 
myocardial infarction. Despite this finding, recent studies 
using C-II pairnitate positron imaging (26,27) have shown 
immediate improvement of regional metabolism after tissue-
type plasminogen activator in the canine model and in a 
small clinical series. The lack of early improvement has 
been attributed to prolonged postischemic ventricular dys-
function or "myocardial stunning" secondary to ischemia-
induced biochemical and ultrastructural alterations (21-24). 
The finding of regional functional improvement at 10 days 
postinfarction, however, contrasts with the conclusions of 
several randomized, pllicebo-controlled studies of intracor-
onary streptokinase (4,6-9). 
Because we found that coronary angioplasty appeared to 
F!pre 5. Marked improvement, at 10 days compared with base-
line, of infarct zone regional wall motion in the distribution of 
reperfusion (lysis) and coronary artery balloon dilation (PTCA) 
compared with segments teperfused without subsequent angio-
plasty or those not reperfused. In the "lysis only" segments, no 
overall improvement was noted. 
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be the predominant contributory factor to functional recov-
ery, the differences in our observations may be due, in large 
part, to the incorporation of mechanical revascularization 
into the study design for all appropriate candidates. In pa-
tients with acute myocardial infarction, prior studies of se-
quential coronary thrombolysis with intracoronary strepto-
kinase and coronary artery balloon angioplasty (28-36) have 
demonstrated both feasibility and improved angiographic 
appearance of the infarct vessel acutely and before hospital 
discharge, but regional functional recovery has not been 
reported. Recently, Yasuno et al. (37) demonstrated a sig-
nificant improvement of regional wall shortening after 
administration of urokinase followed by immediate trans-
luminal coronary angioplasty. Another approach to patients 
with acute infarction is intracoronary administration of 
streptokinase combined with acute surgical revasculariza-
tion, which has been demonstrated (38) to reduce infarct 
size and improve left ventricular function. Several studies 
(39-44) have demonstrated improved global and regional 
Figure 6. At 10 days, there is significant improvement of wall 
motion in reperfused infarct zone segments in patients with ongoing 
chest pain compared with segments in patients without chest pain. 
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Figure 7. The time to reperfusion is plotted against the change 
(.1) in wall motion score (day 10 versus admission) for reperfused 
infarct zone segments, Marked scatter of regional wall motion is 
evident throughout the range of 3 to 7 hours from onset of chest 
pain to coronary thrombolysis. 
myocardial function, both systolic and diastolic, after coro-
nary angioplasty in patients with evidence of reversible tran-
sient ischemia, 
Role of coronary angioplasty. In our study, the im-
portance of coronary angioplasty in promoting functional 
recovery may relate to at least two factors. First, treatment 
of the underlying stenosis, which was severe in all patients, 
abolishes a flow-limiting obstruction and allows "full" 
coronary revascularization (45), which may be crucial for 
functional recovery. Indeed, the coronary flow reserve is 
minimally affected by successful thrombolysis alone, but 
exhibits significant improvement after sequential coronary 
angioplasty (46). Second, by dealing effectively with the 
residual atherosclerotic coronary lesion, there appears to be 
less propensity for reocclusion after initial recanalization 
(28-34). In experimental atherosclerotic, thrombotic occlu-
sion, after treatment with tissue plasminogen activator, we 
found evidence of residual thrombus, which may propagate 
recurrent thrombosis (47). Careful angiographic studies sug-
gest that the incidence of symptomatic reocclusion after 
streptokinase therapy without coronary angioplasty is at least 
20% before hospital discharge and proportionally higher for 
more critical lesions (6,30,48-50). Furthermore, as was 
demonstrated in our series of patients, rethrombosis may 
also be a "silent" phenomenon. Thus, by further improving 
coronary blood flow and removing the nidus for rethrom-
bosis, coronary angioplasty may be a key determinant of 
functional recovery after myocardial infarction. Because 
benefit was seen despite a mean delay of 22 hours between 
thrombolysis and angioplasty, this combined approach may 
prove to be feasible even in hospitals where angioplasty is 
not immediately available, 
Time to reperfusion. In our patients, the duration of 
chest pain before reperfusion did not appear to be inversely 
correlated with functional recovery. If in patients the onset 
of chest pain truly represents the coronary occlusive event, 
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the results in animals are not parallel with our observations 
(51,52). However, several other clinical studies with strep-
tokinase (53-55) have not found the time interval from onset 
of chest pain to recanalization to be of predictive value for 
left ventricular functional improvement. 
Perhaps a more important marker of myocardial sal-
vageability is the presence of chest pain at the time lysis is 
achieved (56). As identified in the current study, there was 
a greater degree of segmental improvement of infarct zone 
regions in patients with ongoing chest pain. Other factors 
such as collateral blood flow or electrocardiographic man-
ifestations did not appear to be related to demonstrable func-
tional recovery. Although other studies have pointed toward 
particular benefit in patients with subtotal coronary occlu-
sion (6,55,57), these patients were excluded a priori from 
entry into the current study. 
Limitations. Several limitations of our study design are 
apparent. First, this is a small, uncontrolled, consecutive 
series of patients. It is clear that spontaneous reperfusion 
may occur in the early phase of acute coronary occlusion 
(57,58). Similarly, there are spontaneous changes of left 
ventricular function in the first 24 hours of acute myocardial 
infarction and throughout the hospital course (59). Clearly, 
it is possible that some patients who had successful tissue 
plasminogen activator-mediated thrombolysis may have had 
early spontaneous reperfusion without this enzyme (56), The 
study design and analysis of data are similar to many of the 
initial studies of patients with myocardial infarction treated 
with streptokinase (12-14,60-62). Although not statisti-
cally significant, the difference in site of infarction between 
patients with and without reperfusion is a function of the 
small. non stratified sample size. Thus, interpretation of such 
a series of consecutive cases must be made with caution 
(63). 
Second, coronary angioplasty was not performed on a 
randomized basis. The selection criteria for this procedure 
were successful reperfusion and suitable coronary artery 
anatomy. Although coronary dilation was associated with 
significant regional wall motion improvement, this may have 
been due to the favorable anatomy itself, which may in tum 
correlate with subsequent functional recovery. Our results 
indicate that reperfused infarct zone segments without sub-
sequent mechanical revascularization lacked significant wall 
motion improvement compared with infarct regions not ini-
tially reperfused. Thus, it remains possible that coronary 
angioplasty was the sole factor responsible for improve-
ment. Indeed, a recent study by O'Neill et al. (64) dem-
onstrated that direct coronary angioplasty was superior to 
intracoronary streptokinase in leading to improved myo-
cardial blood flow and left ventricular function. 
Third, the analysis of regional function relied on visual 
assessment of wall motion on two-dimensional echocardio-
graphic studies, which is a semiquantitative measurement 
(20). Although analysis of regional wall thickening is more 
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quantitative, it requires complete definition of endocardial 
and epicardial outlines, which was not possible in some 
cases, and does not allow integration of various echocar-
diographic planes (65). Visual techniques have been vali-
dated and utilized in many prior studies of acute myocardial 
infarction (66,67). Instead of deriving an overall wall mo-
tion score index (5,10,25,66,67), we used a high threshold 
to define wall motion improvement and kept infarct and 
noninfarct zone segments discrete. 
Although the intravenous route was used in most patients, 
a pretreatment angiogram was required to confirm throm-
bolytic efficacy of tissue plasminogen activator. Thus, an 
intrinsic time delay for initiation of therapy, despite intra-
venous administration, was part of the study design and may 
have impeded the demonstration of more substantial wall 
motion improvement. 
Implications. Our study points to the important poten-
tial role of angioplasty in promoting improvement of re-
gional function after acute coronary artery occlusion. The 
coronary thrombolytic efficacy of tissue-type plasminogen 
activator compares favorably with both intracoronary (4-8) 
and intravenous (10,11 ,50) streptokinase, but there was lit-
tle functional recovery in those patients who did not also 
have successful mechanical revascularization. The salutary 
properties of tissue plasminogen activator, both its relative 
fibrin selectivity and its short half-life, may be of particular 
value in allowing definitive revascularization with coronary 
angioplasty to be achieved safely. Controlled trials are cur-
rently in progress to test the role of second generation throm-
bolytic agents and angioplasty in acute myocardial infarction. 
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